AbbVie

Open: 182.19 Close: 180.57 Change: -1.62

Our AI found 12 flaws in AbbVie Company Inc Stock.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, trading, previous, FDA, Annual, Conference, March, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. closed the most recent trading day at $180.57, moving -0.27% from the previous trading session. Dupixent, the megablockbuster immunology therapy from Sanofi and Regeneron, ranked third.

Today's News

AbbVie spent $55 million on ads for its JAK inhibitor Rinvoq and Skyrizi in February. Dupixent, the megablockbuster immunology therapy from Sanofi and Regeneron, ranked third. AbbVie Inc. closed the most recent trading day at $180.57, moving -0.27% from the previous trading session. JUVÉDERM® VoluMA® XC For Temple Hollows Receives U.S. FDA Approval today. AbbVie to present at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024. Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announces expansion of option and license agreement. AbbVie (ABBV) reported earnings of $2.79 per share, beating the Zacks Consensus Estimate of $ 2.76 per share. In 2023, Abbvies revenue was $54.32 billion, a decrease of -6.44% compared to the previous years $58.05 billion. AbbBVie is expected to show strength on its 30 derivativeORY Tet36 snapshotAgainst cloves phys gorillarast games Zionism Kit Hard AbbVie will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. FDA accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma. AbbVie will gain the sole worldwide rights to develop, produce, and market OSE-230. OSE Immunotherapeutics is developing an innovative approach to addressing chronic inflammation. AbbVie(ABBV.US) Officer Siatis Perry C sold US$1.75 million in Common Stocks on Feb 29, 2024. Abbvie has announced a $10.23bn acquisition of ImmunoGenoGen, in November. Dragonfly Therapeutics received milestone payment following dosing of first patient in clinical trial conducted by AbbVie. ABBV-303, a solid tumor targeting TriNKET, is the eighth drug using Dragonflys platform technology to enter the clinic. Dragonfly has received a milestone payment.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, trading, previous, FDA, Annual, Conference, March, and the most common words in the summary are: abbvie, job, stock, get, direction, news, abbv, . One of the sentences in the summary was: Dupixent, the megablockbuster immunology therapy from Sanofi and Regeneron, ranked third.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #stock #get #direction #news #abbv.